中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

Effect of Xiaozhang plaster in treatment of cirrhotic ascites and its influence on the renin-angiotensin-aldosterone system

DOI: 10.3969/j.issn.1001-5256.2019.07.015
Research funding:

 

  • Received Date: 2019-03-01
  • Published Date: 2019-07-20
  • Objective To investigate the effect of Xiaozhang plaster in the treatment of cirrhotic ascites and its influence on the renin-angiotensin-aldosterone system. Methods A total of 220 patients with cirrhotic ascites who were hospitalized in Department of Gastroenterology in Shanghai Baoshan Integrated Traditional Chinese and Western Medical Hospital from March 2015 to March 2016 were enrolled and divided into routine treatment group with 60 patients, Xiaozhang plaster group with 60 patients, and terlipressin group with 100 patients. The patients in the routine treatment group received the routine treatment of cirrhotic ascites with a limitation of the dose of diuretics, those in the Xiaozhang plaster group were treated with Xiaozhang plaster in addition to the routine treatment, and those in the terlipressin group were treated with terlipressin in addition to the routine treatment. The three groups were observed in terms of related outcome measures ( depth of ascites, 24-hour urine volume, abdominal circumference, body weight, and Child-Pugh score) , symptoms and signs ( abdominal distension, diet, passage of gas by anus, and defecation) , hepatic and renal function, electrolytes, routine blood test results, coagulation function, portal vein diameter, glomerular filtration rate, and vasoactive substances [plasma renin activity ( PRA) , angiotensin Ⅱ ( AngⅡ) , and aldosterone ( ALD) ]. An analysis of variance was used for comparison of continuous data between multiple groups, and the least significant difference t-test was used for comparison within each group. Results There were significant differences between the three groups in depth of ascites, urine volume, abdominal circumference, Child-Pugh score, AngⅡ level, and ALD level on days 14 and 28 of treatment ( day14: F = 6. 566, 16. 236, 10. 856, 5. 727, 41. 860, and 20. 845, all P < 0. 05; day 28: F = 169. 311, 67. 686, 13. 521, 39. 721, 159. 256, and 80. 400, all P < 0. 05) . There were significant differences between the three groups in body weight and PRA level on day 28 of treatment ( F = 5. 068 and 0. 012, both P < 0. 05) . There were also significant differences between the three groups in the scores of abdominal distension, passage of gas by anus, and defecation on days 7, 14, and 28 of treatment ( day 7: F = 38. 311, 33. 405, and 33. 996, all P < 0. 05; day 14: F = 64. 414, 39. 481, and 52. 455, all P < 0. 05; day 28: F = 57. 596, 23. 041, and 47. 576, all P < 0. 05) . Conclusion Both Xiaozhang plaster and terlipressin can reduce ascites volume in patients with cirrhotic ascites, but they may have different action characteristics. Xiaozhang plaster is superior to terlipressin in the treatment of cirrhotic ascites and can significantly improve clinical symptoms, possibly by reducing the levels of PRA, AngⅡ, and ALD.

     

  • [1]DONG CL, YU MD, TAO R, et al.Clinical value of moxibustion combined with sticking therapy at Shenque point in improving cirrhotic ascites[J].J Changchun Univ Chin Med, 2018, 34 (3) :525-527. (in Chinese) 董春玲, 俞美定, 陶茹, 等.艾灸联合神阙穴贴敷改善肝硬化腹水[J].长春中医药大学学报, 2018, 34 (3) :525-527.
    [2]Chinese Society of Infectious Diseases and Parasitology and Chinese Society of Hepatology, Chinese Medical Association.Regimens for the prevention and treatment of viral hepatitis[J].Chin JIntern Med, 2001, 40 (1) :62-68. (in Chinese) 中华医学会传染病与寄生虫病学分会、肝病学分会.病毒性肝炎防治方案[J].中华内科杂志, 2001, 40 (1) :62-68.
    [3]Chinese Society of Hepatology, Chinese Medical Association.Guidelines on the management of ascites and complications in cirrhosis[J].J Clin Hepatol, 2017, 33 (10) :1847-1863. (in Chinese) 中华医学会肝病学分会.肝硬化腹水及相关并发症的诊疗指南[J].临床肝胆病杂志, 2017, 33 (10) :1847-1863.
    [4] China Association of Chinese Medicine.Guidelines for the diagnosis and treatment of common diseases in Chinese internal medicine:Diseases of traditional Chinese medicine[M].Beijing:China Press of Traditional Chinese Medicine, 2008:95-97. (in Chinese) 中华中医药学会.中医内科常见病诊疗指南·中医病证部分[M].北京:中国中医药出版社, 2008:95-97.
    [5]LIU CH, ZHANG YL, FENG NP, et al.Effects of syndrome dependent umbilical sticking with shizhang cataplasm and xuzhang cataplasm in treating liver cirrhosis caused ascites[J].Chin J Integr Trad West Med, 2006, 26 (5) :411-414. (in Chinese) 刘成海, 张雅丽, 冯年平, 等.实胀方与虚胀方辨证敷脐对肝硬化腹水的作用[J].中国中西医结合杂志, 2006, 26 (5) :411-414.
    [6]Interventional Group, Chinese Society of Radiology, Chinese Medical Association.Expert consensus on transjugular intrahepatic portosystemic shunt[J].J Clin Hepatol, 2017, 33 (7) :1218-1228. (in Chinese) 中华医学会放射学分会介入学组.经颈静脉肝内门体分流术专家共识[J].临床肝胆病杂志, 2017, 33 (7) :1218-1228.
    [7]ZHANG HT, LI QY, LYU WH, et al.Clinical efficacy of terlipressin combined with human albumin for refractory ascites due to cirrhosis[J].Guangxi Med J, 2018, 40 (7) :759-762. (in Chinese) 张会涛, 李秋雅, 吕文浩, 等.特利加压素联合人血白蛋白治疗肝硬化顽固性腹水的临床疗效[J].广西医学, 2018, 40 (7) :759-762.
    [8]PAN CF, ZHANG YL, CAI JP, et al.Umbilical compress therapy for cirrhotic ascites[J].Chin J Integr Tradit West Med Liver Dis, 2004, 14 (2) :126-128. (in Chinese) 潘传芳, 张雅丽, 蔡俊萍, 等.肝硬化腹水的敷脐疗法[J].中西医结合肝病杂志, 2004, 14 (2) :126-128.
    [9]LEI L.Clinical effect of traditional Chinese medicine umbilical compress therapy in treatment of cirrhotic ascites:An analysis of 41 cases[J].Chin J Integr Tradit West Med Liver Dis, 1994, 4 (2) :41. (in Chinese) 雷陵.中药敷脐为主治疗肝硬化腹水41例[J].中西医结合肝病杂志, 1994, 4 (2) :41.
    [10]SECCHI MF, CRESCENZI M, RUSSO FP, et al.A novel role for heparanase in the onset of liver fibrosis[J].Dig Liver Dis, 2017, 49 (1) :e20-e21.
    [11]STOLL D, YOKOTA R, ARAGAO DS, et al.Modulation of the intracrine renin angiotensin system in mesangial cells submitted to aldosterone stimulus[J].FASEB J, 2017, 31 (1 Supplement) :1031.6.
  • Cited by

    Periodical cited type(15)

    1. 梅梦如,李雨,陈炳东,刘美燕,卢昌林,刘志芳,黄小桃,林镛,颜耿杰,龙富立. 中医药治疗肝硬化腹水的作用机制及临床应用概述. 辽宁中医杂志. 2025(01): 195-199 .
    2. 肖准,马素平,杨芳明,刘杨春,费景兰,赵文霞. 中医外治法在肝硬化治疗中的应用及潜在机制. 中西医结合肝病杂志. 2024(07): 669-672 .
    3. 刘娴娟. 特利加压素联合腹水浓缩回输术对肝硬化并顽固性腹水患者肾功能及生命质量的影响. 医学理论与实践. 2023(08): 1322-1324 .
    4. 詹怀勇. 消胀贴敷脐联合常规西药治疗乙型病毒性肝炎肝硬化腹水的临床效果. 临床医学研究与实践. 2022(01): 154-157 .
    5. 李瑛,胡振斌,徐昆,张旭,黄家程. 中医药治疗肝硬化腹水临床研究概述. 中西医结合肝病杂志. 2022(02): 185-188 .
    6. 田顺正,白金川. 中西医结合治疗肝硬化顽固性腹水疗效分析. 实用中医药杂志. 2022(03): 463-465 .
    7. 宋振恒,刘茵,王挺帅,唐秋媛,黄永林. 中医药治疗肝硬化腹水临床研究进展. 大众科技. 2022(02): 78-81+52 .
    8. 胡燕明,余建平,盛吉芳. 特利加压素联合中药敷脐在肝硬化腹水患者中的应用. 中国现代医生. 2022(24): 69-73 .
    9. 柳海艳,王茜,李怡文,刘云翔,陈绍红,钟赣生. 甘遂半夏汤中甘遂甘草反药组合加减应用对腹水大鼠利水及免疫方面的影响. 中华中医药杂志. 2022(11): 6271-6278 .
    10. 孔祥钢,刘斌. 苓桂术甘汤联合前列地尔治疗肝硬化腹水患者的临床效果分析. 中国医学创新. 2021(19): 57-61 .
    11. 秦维,祝素平,郑艳丽,霍玉玲,王丹. 超滤腹水回输与腹腔置管引流对肾血管调节因子、肝肾功能、电解质的影响效果观察. 中国中西医结合肾病杂志. 2021(07): 617-619 .
    12. 任洁,胡经文,郭统帅,何明俊,刘富强,牟建军. 高盐饮食对盐敏感性高血压大鼠肾脏损伤的影响. 安徽医学. 2020(08): 872-875 .
    13. 魏晓梅. 益气舒肝方辅治乙肝肝硬化腹水临床观察. 实用中医药杂志. 2020(09): 1172-1173 .
    14. 张瑞年. 消胀贴外敷神阙穴联合耳穴压丸治疗肝硬化腹水的临床研究. 数理医药学杂志. 2020(10): 1537-1538 .
    15. 王娜,吉慧聪,周慧莹. PDCA模式结合临床路径护理在肝硬化腹水患者中的应用效果. 中国实用护理杂志. 2020(24): 1852-1856 .

    Other cited types(3)

  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1443) PDF downloads(252) Cited by(18)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return